Loading
A phase 2 trial in lung cancer, run by Soroka University Medical Center, now recruiting.
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer is a phase 2, randomised interventional study registered as NCT05502913 by Soroka University Medical Center, with a registry enrolment figure of 80 participants, started 2023-09-01 and due to reach its primary completion in 2025-06-30. Interventions recorded: Antibiotics; FMT (Fecal Microbiota Transplantation). Conditions listed: Metastatic Lung Cancer. Primary outcome: Progression-free Survival (PFS). Sites: Israel. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.